Skip to main content

Table 1 Participant characteristics

From: Lower circulating endocannabinoid levels in children with autism spectrum disorder

  Neurotypical control Children with ASD
N 93 93
Age 11.8 ± 4.3 13.1 ± 4.1^
% male 79% 79%
BMI 21.0 ± 4.2 20.4 ± 5.5
Epilepsy comorbidity 0% 10%
High ASD symptoms severity
 ADOS comparison score = 8–10   77%
 VABS standard score ≤ 70   88%
 CARS total score ≥ 37   81%
 SRS t scores ≥ 75   86%
Psychotropic medications*
 Any   80%
 Antipsychotic   56%
 SSRIs   23%
 Stimulants   15%
 Antiepileptic (mood stabilizers)   13%
 Benzodiazepines   8%
 Others   5%
  1. ^Significant age difference (P = 0.040). The BMI difference was not significant
  2. *Medications were stable for at least 1 month before blood collection. Antipsychotic (n): risperidone (21), aripiprazole (16), clotiapine (10), periciazine (10), olanzapine (5), promethazine (3), quetiapine fumarate (seroquel, 3), methotrimeprazine (1). SSRIs selective serotonin reuptake inhibitors (n): fluoxetine (15), fluvoxamine (2), sertraline (2), escitalopram (1), trazodone (1). Stimulants (n): methylphenidate (11), lisdexamfetamine (2). Antiepileptic (n): valproic acid (7), carbamazepine (1), lamotrigine (1), topiramate (1), stiripentol (1), sulthiame (1). Benzodiazepines (n): clobazam (3), clonazepam (3), zolpidem (1). Others (n): guanfacine (2), propranolol (2), enalapril (1)